Navigating the Path to a Diagnosis
At a Glance
Doctors diagnose Nakajo-Nishimura syndrome by combining early fevers, characteristic skin rashes, progressive loss of fat and muscle, and broad genetic testing. An interferon score can support the diagnosis but cannot confirm NNS on its own.
Getting to a diagnosis of Nakajo-Nishimura Syndrome (NNS) is often described as a “diagnostic odyssey.” Because it is so rare, it is common for families to spend years seeing different specialists before the pieces of the puzzle—fevers, skin rashes, and fat loss—are finally connected [1][2]. Doctors today rely on a combination of clinical pattern recognition, specialized blood work, and advanced genetic testing to evaluate the diagnosis [3].
The Clinical Pattern: The First Clue
The most important tool a doctor has is the medical history. Specialists look for a specific “signature” of symptoms that appear very early in life, often before age one [1]. This includes:
- Recurrent or persistent fevers [2].
- Rashes that look like chilblains (pernio-like) or tender red bumps (panniculitic nodules) [1][4].
- The progressive loss of fat and muscle, especially in the face and upper body [1].
- Joint stiffness or fingers that appear long and rounded at the tips (clubbing) [4].
The Role of Genetics
While classic NNS is caused by biallelic mutations (inheriting a mutation from both parents) in the PSMB8 gene, we now know that variants in several other genes can cause nearly identical symptoms [1][5].
- Genetic Panels: Instead of testing just one gene, doctors now recommend using a broad autoinflammatory panel or whole-exome sequencing. This ensures they don’t miss variants in other proteasome-related genes like PSMB9, PSMB4, PSMB10, or POMP, which cause different conditions under the broader PRAAS umbrella [5][6][7].
- Inheritance Patterns: Because some variants are of “uncertain significance” (VUS) or have different inheritance patterns (dominant or digenic), interpreting the results requires a clinical geneticist or genetic counselor [6][8]. They can discuss recurrence risks, parental carrier testing, and whether siblings should be evaluated.
The Type I Interferon Signature
A breakthrough in evaluating NNS and other PRAAS conditions is the Type I interferon signature (or interferon score) [6].
Interferons are proteins your immune system uses to fight viruses. In conditions like NNS, the body acts as if it is fighting a permanent virus, even when none is present [6]. Some specialized centers measure this by looking at a specific set of 28 genes in the blood [9]. An elevated score supports the presence of an interferonopathy [6]. While this score is a supportive biomarker, it isn’t a definitive “yes or no” for NNS specifically—other infections or inflammatory conditions can also cause high scores [10].
Look-Alike Conditions
Because the symptoms of NNS can overlap with other diseases, your doctor must rule out “look-alikes,” including:
- SAVI (STING-Associated Vasculopathy with Onset in Infancy): Also has an interferon signature but often involves severe lung disease and more significant skin ulcers [11][12].
- Juvenile Dermatomyositis: Causes muscle weakness and skin rashes but typically shows different markers in the blood (like high CK enzymes).
- Lupus (SLE): Can share skin and joint symptoms, but specific autoantibody tests and a careful clinical synthesis help distinguish it [12].
Diagnosis Completeness Checklist
If you are currently in the middle of a diagnostic workup, ensure your medical team has completed or considered the following:
| Test Category | What to Look For | Why It Matters |
|---|---|---|
| Genetic Panel | Broad panel (including PSMB8, PSMB9, POMP, etc.) | Missing one gene could lead to a “negative” result in someone who actually has a PRAAS condition [5]. |
| Interferon Score | Standardized signature (if available) | Supports the “interferonopathy” status, though not universally required for diagnosis [9]. |
| Inflammatory Markers | CRP, ESR, and Ferritin | Measures the overall level of active inflammation in the body [2]. |
| Targeted Imaging | Ultrasounds or MRIs | Ordered only if specific physical or neurological symptoms warrant investigating organ size or joints. Routine brain CTs are avoided to limit radiation [4][2]. |
| Biopsy (Optional) | Skin or muscle biopsy | Usually not needed for the final diagnosis, but can help rule out other “look-alikes” if the genetics are unclear [13][2]. |
Confirming the diagnosis is a significant milestone. It moves you from “searching for answers” to “planning for treatment” [3].
Common questions in this guide
How is Nakajo-Nishimura syndrome diagnosed?
What genes are tested when NNS is suspected?
What does an interferon score tell you about NNS?
Can NNS look like other diseases?
What does a variant of uncertain significance mean on an NNS genetic test?
Are imaging or biopsy always needed to diagnose NNS?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
About genetic testing
Would a broad genetic panel or whole-exome sequencing be recommended in my situation?
About the interferon score
What is an interferon score, and would doctors measure one for me?
Other conditions considered
What other conditions do doctors need to rule out before confirming NNS?
Get notified when new evidence is published on Nakajo-Nishimura syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (13)
- 1
Nakajo-Nishimura syndrome and related proteasome-associated autoinflammatory syndromes.
Ohmura K
Journal of inflammation research 2019; (12()):259-265 doi:10.2147/JIR.S194098.
PMID: 31576159 - 2
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome: A Systemic Review.
Altom A, Khader SAE, Gad AG, et al.
The American Journal of dermatopathology 2023; (45(6)):355-370 doi:10.1097/DAD.0000000000002345.
PMID: 37191371 - 3
The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.
Cetin Gedik K, Lamot L, Romano M, et al.
Annals of the rheumatic diseases 2022; (81(5)):601-613 doi:10.1136/annrheumdis-2021-221814.
PMID: 35086813 - 4
A Chinese case of Nakajo-Nishimura syndrome with novel compound heterozygous mutations of the PSMB8 gene.
Jia T, Zheng Y, Feng C, et al.
BMC medical genetics 2020; (21(1)):126 doi:10.1186/s12881-020-01060-8.
PMID: 32513120 - 5
Contribution of the Unfolded Protein Response (UPR) to the Pathogenesis of Proteasome-Associated Autoinflammatory Syndromes (PRAAS).
Ebstein F, Poli Harlowe MC, Studencka-Turski M, Krüger E
Frontiers in immunology 2019; (10()):2756 doi:10.3389/fimmu.2019.02756.
PMID: 31827472 - 6
Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production.
Brehm A, Liu Y, Sheikh A, et al.
The Journal of clinical investigation 2015; (125(11)):4196-211.
PMID: 26524591 - 7
Identification of eight novel proteasome variants in five unrelated cases of proteasome-associated autoinflammatory syndromes (PRAAS).
Papendorf JJ, Ebstein F, Alehashemi S, et al.
Frontiers in immunology 2023; (14()):1190104 doi:10.3389/fimmu.2023.1190104.
PMID: 37600812 - 8
Monoallelic PSMB8 variants cause PRAAS with immunodeficiency through impaired immunoproteasome assembly.
Wijngaard R, van der Made CI, Kalkan Uçar S, et al.
American journal of human genetics 2026; (113(6)):1214-1232 doi:10.1016/j.ajhg.2026.04.015.
PMID: 42167218 - 9
Development of a Validated Interferon Score Using NanoString Technology.
Kim H, de Jesus AA, Brooks SR, et al.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2018; (38(4)):171-185 doi:10.1089/jir.2017.0127.
PMID: 29638206 - 10
Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases.
de Jesus AA, Hou Y, Brooks S, et al.
The Journal of clinical investigation 2020; (130(4)):1669-1682.
PMID: 31874111 - 11
Vasculitis in Systemic Autoinflammatory Diseases.
Demir S, Sag E, Dedeoglu F, Ozen S
Frontiers in pediatrics 2018; (6()):377 doi:10.3389/fped.2018.00377.
PMID: 30560109 - 12
Unraveling the diagnostic odyssey: stimulator of interferon gene-associated vasculopathy with onset in infancy in a 30-year-old female.
Kim HR, Lim SH, Park JS, et al.
Journal of rheumatic diseases 2024; (31(3)):182-187 doi:10.4078/jrd.2023.0075.
PMID: 38957365 - 13
Myositis with sarcoplasmic inclusions in Nakajo-Nishimura syndrome: a genetic inflammatory myopathy.
Ayaki T, Murata K, Kanazawa N, et al.
Neuropathology and applied neurobiology 2020; (46(6)):579-587 doi:10.1111/nan.12614.
PMID: 32144790
This page explains how clinicians evaluate suspected Nakajo-Nishimura syndrome for educational purposes and does not constitute medical advice. A clinical geneticist, genetic counselor, or treating specialist should interpret individual results and recommend testing.